Invasive Malignant Neoplasm — Trials

Invasive Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 604
Recruiting: 302
Ph III recruiting: 36
Growth YoY: +27.2%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (283)

clinicaltrialsPublishedShowing 51–100 of 293 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02101775	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	Phase 2	124	National Cancer Institute (NCI)NIH	3	Sep 10, 2026	clinicaltrials
NCT02595892	Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	Phase 2	70	National Cancer Institute (NCI)NIH	1	Sep 9, 2026